| Amber Joann Gilbert, FNP | |
|
2300 Biddle Ave, Wyandotte, MI 48192-4650 | |
| (734) 246-5705 | |
| Not Available |
| Full Name | Amber Joann Gilbert |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 2300 Biddle Ave, Wyandotte, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992392070 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 4704266399 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Amber Joann Gilbert, FNP 28755 Sugar Island Ct, Gibraltar, MI 48173-9571 Ph: (734) 301-3761 | Amber Joann Gilbert, FNP 2300 Biddle Ave, Wyandotte, MI 48192-4650 Ph: (734) 246-5705 |
News Archive
A new blood glucose monitoring (BGM) system from Bayer, the CONTOUR Next EZ meter and CONTOUR Next test strips, proved easy to use and highly accurate in the hands of intended users - patients and their healthcare professionals (HCPs) - according to a clinical study presented at the American Diabetes Association 72nd Scientific Sessions in Philadelphia, PA.
A University of Pennsylvania researcher has discovered that the common selective serotonin reuptake inhibitor (SSRI) citalopram arrested the growth of amyloid beta, a peptide in the brain that clusters in plaques that are thought to trigger the development of Alzheimer's disease (AD).
Researchers from the Molecular Cancer group at the Hospital del Mar Medical Research Institute and doctors from Hospital del Mar, have demonstrated the effectiveness of a drug for treating metastatic bladder cancer in patients who did not respond to the usual treatment.
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.
Elan Corporation, plc and Transition Therapeutics, Inc today announced the results of a Phase 2 placebo-controlled study in 351 patients with mild to moderate Alzheimer's disease who received study drug for up to 18 months (Study AD201). Study subjects with MMSE scores between 16 and 26 received ELND005 oral doses of 250 mg, 1000 mg or 2000 mg twice daily or matching placebo. The study's cognitive (NTB) and functional (ADCS-ADL) co - primary endpoints did not achieve statistical significance.
› Verified 7 days ago
Dr. Sami M Baraka, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1622 Eureka Rd, Wyandotte, MI 48192 Phone: 734-282-0600 Fax: 734-282-0500 | |
Brittany J Regalado, FNP-C Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2201 Ford Ave, Wyandotte, MI 48192 Phone: 734-258-8835 | |
Charles Xin, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Biddle Ave, Wyandotte, MI 48192 Phone: 734-284-2026 | |
Dr. Vinod K Mohey, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 995 Ford Ave, Wyandotte, MI 48192 Phone: 734-284-3100 Fax: 734-284-8212 | |
Lubna Manzoor, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2070 Biddle Ave Ste 2, Wyandotte, MI 48192 Phone: 734-282-2020 Fax: 734-282-2002 | |
Rebecca Kate Busk-sutton, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2333 Biddle Ave, Wyandotte, MI 48192 Phone: 734-246-6000 | |
Robert Moore, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 Biddle Ave, Wyandotte, MI 48192 Phone: 734-284-2026 |